Levodopa in the treatment of Parkinsonism.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001921:Brain / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004952:Esters; D006801:Humans; D006834:Hydrazines / Q000494:pharmacology; D020149:Manganese Poisoning; D008745:Methylation; D008750:Methyldopa / Q000494:pharmacology; D051379:Mice; D009068:Movement / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010648:Phenylacetates / Q000494:pharmacology
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004952:Esters; D006834:Hydrazines; D010648:Phenylacetates; D008750:Methyldopa; D004295:Dihydroxyphenylalanine; D001058:Apomorphine; D004298:Dopamine